Therapy Detail

Therapy Name Ipilimumab + Pembrolizumab
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Ipilimumab Yervoy BMS-734016 CTLA4 Antibody 11 Immune Checkpoint Inhibitor 99 Yervoy (ipilimumab) is an antibody that binds to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), causing increased T-cell activation (PMID: 28891423). Yervoy (ipilimumab) is FDA approved for use in patients with metastatic melanoma, including patients 12 years or older, and in combination with Opdivo (nivolumab) for intermediate or poor-risk renal cell carcinoma and microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (FDA.gov).
Pembrolizumab Keytruda MK-3475 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 51 Keytruda (pembrolizumab) is an antibody against PD-1, resulting in activation of T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved for use in patients with melanoma, small cell lung cancer, HNSCC, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, hepatocellular carcinoma, Merkel cell carcinoma, MSI-H or dMMR solid tumors, PD-L1 expressing NSCLC, gastric cancer, GEJ adenocarcinoma, and cervical cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, in combination with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC, and in combination with axitinib for renal cell carcinoma (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown uveal melanoma no benefit Ipilimumab + Pembrolizumab Case Reports/Case Series Actionable In a clinical study, Yervoy (ipilimumab) and Keytruda (pembrolizumab) combination treatment resulted in an objective response rate of 0% (0/9) and a disease control rate of 56% (5/9) in patients with uveal melanoma, with a median overall survival of 18.4 months (PMID: 29988983). 29988983

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status
NCT02039674 Phase Ib/II Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pemetrexed Ipilimumab + Pembrolizumab Erlotinib + Pembrolizumab Gefitinib + Pembrolizumab A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021) Active, not recruiting
NCT02743819 Phase II Ipilimumab + Pembrolizumab Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody Recruiting
NCT03302234 Phase III Pembrolizumab Ipilimumab + Pembrolizumab Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598) Recruiting
NCT03873818 Phase II Ipilimumab + Pembrolizumab Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain Recruiting
NCT03396952 Phase II Ipilimumab + Pembrolizumab Prostaglandin Inhibition and PD-1/CTLA4 Blockade in Melanoma Recruiting


Additional content available in CKB BOOST